Veracyte, Inc.NASDAQ: VCYT

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

· Issued by Veracyte, Inc. via Business Wire

Summary by 6ix AI

Veracyte, Inc., a cancer diagnostics company, will release its financial results for the second quarter 2026 after the market closes on Thursday, July 30, 2026, and will host a conference call and webcast at 4:30 p.m. Eastern Time the same day.

Key details

  • Management will discuss the financial results and give a general business update on the call, which will be webcast live from the company's website, with a replay available there after the live broadcast.

6ix AI wrote this summary from the release below and checked it against the release.

SOUTH SAN FRANCISCO, Calif., July 09, 2026--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company's molecular tests assess the unique biology of each patient's tumor to help clinicians answer essential questions about cancer care. Veracyte's Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company's portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte's website or follow the company on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260709945913/en/

Contacts

Investors
Kelly Gura
[email protected]

Media
Molly Cornbleet
[email protected]
+1-650-351-8780

View original source (Business Wire)Veracyte, Inc. on 6ix

Story so far

Earlier from Veracyte

Later from Veracyte

All Veracyte news releases